SCHEMBL3692246

SCHEMBL3692246

CCOC(=O)/C=C/c1cc(Br)c(O[Si](C)(C)C(C)(C)C)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.51
TNFRSF1A P19438 3/20 0.49
FDPS P14324 1/20 0.49
ALOX5 P09917 1/20 0.46
KDM4E B2RXH2 3/20 0.46
MET P08581 3/20 0.44
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.43
DRD2 P14416 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP1B1 Q16678 1/20 0.42
BCHE P06276 2/20 0.41
ACHE P22303 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3692244 1.00 MAOB (0.51) MAOBTNFRSF1AFDPSALOX5KDM4E
SCHEMBL31098822 0.82 FDPS (0.63) MAOBFDPSKDM4EALDH1A1HPGD
SCHEMBL12098251 0.81 BACE1 (0.49) MAOBALOX5KDM4EALDH1A1HPGD
SCHEMBL12098248 0.81 BACE1 (0.49) MAOBALOX5KDM4EALDH1A1HPGD
SCHEMBL8772845 0.79 MAOB (0.68) MAOBFDPSALOX5KDM4EMET
SCHEMBL8772838 0.79 MAOB (0.68) MAOBFDPSALOX5KDM4EMET
SCHEMBL12098058 0.77 KDM4E (0.66) KDM4EALDH1A1HPGDGAA
SCHEMBL12098059 0.77 KDM4E (0.66) KDM4EALDH1A1HPGDGAA
SCHEMBL3688221 0.77 CCNC (0.54) MAOBFDPSKDM4EALDH1A1CYP3A4
SCHEMBL3688218 0.77 CCNC (0.54) MAOBFDPSKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 US disclosed
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-03-05 US disclosed
US-7470807-B2 Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate ASAHI KASEI PHARMA CORPORATION (JP) 2008-12-30 US disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 US disclosed
EP-1660427-A4 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2006-12-20 EP disclosed
EP-1660427-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2006-05-31 EP disclosed
WO-2005016862-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORPORATION (JP) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 MAOB 886/4885TNFRSF1A 783/4885FDPS 701/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 MAOB 886/4885TNFRSF1A 783/4885FDPS 701/4885
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 MAOB 886/4885TNFRSF1A 783/4885FDPS 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.